American Healthcare REIT, Inc. (AHR)
(Delayed Data from NYSE)
$26.17 USD
-0.43 (-1.62%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $26.18 +0.01 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.17 USD
-0.43 (-1.62%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $26.18 +0.01 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Zacks News
NexPoint Real Estate Finance to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
NREF's third-quarter 2024 results are likely to gain from declining mortgage rates, although a decrease in NII poses a challenge.
Key Factors Influencing Two Harbors Investment's Q3 Earnings
by Zacks Equity Research
TWO's third-quarter 2024 results are expected to benefit from lower mortgage rates, though the negative NII remains a challenge.
Is the Options Market Predicting a Spike in American Healthcare REIT, Inc. (AHR) Stock?
by Zacks Equity Research
Investors need to pay close attention to American Healthcare REIT, Inc. (AHR) stock based on the movements in the options market lately.
Key Factors to Know Ahead of ARMOUR Residential REIT's Q3 Earnings
by Zacks Equity Research
ARR's third-quarter 2024 results are likely to reflect the impacts of high funding costs. High prepayment speed is expected to have supported.
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q3 earnings are likely to have benefited from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Annaly Scheduled to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
NLY's third-quarter 2024 results are likely to reflect the impacts of increased funding costs. High prepayment speed is likely to have aided.
Best Momentum Stocks to Buy for September 27th
by Zacks Equity Research
MHO, RACE and AHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 27, 2024.
American Healthcare REIT (AHR) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
American Healthcare REIT (AHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for September 23rd
by Zacks Equity Research
AU, AHR and HWM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23, 2024.
New Strong Buy Stocks for September 23rd
by Zacks Equity Research
OPRA, SBSI, AU, AHR and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 23, 2024.
Implied Volatility Surging for American Healthcare (AHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to American Healthcare (AHR) stock based on the movements in the options market lately.
Implied Volatility Surging for American Healthcare (AHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to American Healthcare (AHR) stock based on the movements in the options market lately.
Is a Surprise Coming for American Healthcare (AHR) This Earnings Season?
by Zacks Equity Research
American Healthcare (AHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.